Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
P24723

UPID:
KPCL_HUMAN

ALTERNATIVE NAMES:
PKC-L; nPKC-eta

ALTERNATIVE UPACC:
P24723; B4DJN5; Q16246; Q8NE03

BACKGROUND:
The Protein kinase C eta type, known as PKC-L or nPKC-eta, is essential for cell differentiation, maintaining epithelial tight junctions, and foam cell formation. It inhibits CDK2 kinase activity, leading to G1 arrest in keratinocytes, and is involved in the regulation of the mTOR and PI3K/AKT pathways for glioblastoma cell proliferation. Additionally, it plays a role in the protection against irradiation-induced apoptosis in glioblastoma cells.

THERAPEUTIC SIGNIFICANCE:
Protein kinase C eta type's critical functions in ischemic stroke, cell cycle regulation, and apoptosis make it a key target for developing treatments for neurological conditions and cancer. Exploring the therapeutic potential of Protein kinase C eta type could revolutionize treatment paradigms.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.